{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:00:26Z","timestamp":1790290826943,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.lfs.2022.120931","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:38:56Z","timestamp":1662464336000},"page":"120931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Permixon\u00ae, hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells"],"prefix":"10.1016","volume":"308","author":[{"given":"Alexander","family":"Tamalunas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Wendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Vigodski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ciotkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Rutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ledderose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kolben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Magistro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hennenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.120931_bb0005","series-title":"Presented at the EAU Annual Congress Milan 2021","article-title":"Management of non-neurogenic male LUTS. EAU guidelines","author":"Gravas","year":"2021"},{"key":"10.1016\/j.lfs.2022.120931_bb0010","first-page":"1","article-title":"Overview on the lower urinary tract","volume":"202","author":"Chapple","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"Suppl. 9","key":"10.1016\/j.lfs.2022.120931_bb0015","first-page":"S3","article-title":"Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia","volume":"6","author":"Lepor","year":"2004","journal-title":"Rev. Urol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120931_bb0020","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"73","author":"Nambiar","year":"2018","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.lfs.2022.120931_bb0025","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int."},{"issue":"7","key":"10.1016\/j.lfs.2022.120931_bb0030","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/nau.22467","article-title":"Prostatic alpha1-adrenoceptors: new concepts of function, regulation, and intracellular signaling","volume":"33","author":"Hennenberg","year":"2014","journal-title":"Neurourol. Urodyn."},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","article-title":"Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study","volume":"68","author":"Cindolo","year":"2014","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.lfs.2022.120931_bb0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13685538.2018.1548589","article-title":"Post-finasteride syndrome - does it really exist?","volume":"22","author":"Maksym","year":"2019","journal-title":"Aging Male"},{"issue":"5","key":"10.1016\/j.lfs.2022.120931_bb0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1742-1241.2010.02626.x","article-title":"Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature","volume":"65","author":"Sexton","year":"2011","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.lfs.2022.120931_bb0050","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2010.02449.x","article-title":"Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder","volume":"64","author":"Wagg","year":"2010","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"10.1016\/j.lfs.2022.120931_bb0055","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bju.12773","article-title":"Mirabegron the first beta3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies","volume":"113","author":"Chapple","year":"2014","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bph.13367","article-title":"Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3 -adrenoceptor activation and alpha1 -adrenoceptor blockade","volume":"173","author":"Alexandre","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2022.120931_bb0065","article-title":"Concentration-dependent alpha1-adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by mirabegron in the human prostate","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120931_bb0070","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/jpet.121.001029","article-title":"Inhibition of full smooth muscle contraction in isolated human detrusor tissues by mirabegron is limited to off-target inhibition of neurogenic contractions","volume":"381","author":"Huang","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2011.03.054","article-title":"The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update","volume":"60","author":"Athanasopoulos","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.lfs.2022.120931_bb0080","first-page":"1","article-title":"Choosing a specialist: an explanatory study of factors influencing patients in choosing a urologist","author":"Tamalunas","year":"2021","journal-title":"Urol. Int."},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MOU.0b013e3282f0d5c8","article-title":"Plant extracts: sense or nonsense?","volume":"18","author":"Madersbacher","year":"2008","journal-title":"Curr. Opin. Urol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.pcan.4500746","article-title":"Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract","volume":"7","author":"Habib","year":"2004","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"10.1016\/j.lfs.2022.120931_bb0095","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euf.2016.04.002","article-title":"Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Novara","year":"2016","journal-title":"Eur. Urol. Focus"},{"issue":"6","key":"10.1016\/j.lfs.2022.120931_bb0100","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bju.14362","volume":"122","author":"Vela-Navarrete","year":"2018","journal-title":"BJU Int."},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0105","doi-asserted-by":"crossref","first-page":"19401","DOI":"10.1038\/s41598-021-98586-5","article-title":"Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients","volume":"11","author":"Alcaraz","year":"2021","journal-title":"Sci. Rep."},{"issue":"5 Pt 1","key":"10.1016\/j.lfs.2022.120931_bb0110","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1097\/01.ju.0000140503.11467.8e","article-title":"Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action","volume":"172","author":"Buck","year":"2004","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/(SICI)1097-0045(19990215)38:3<208::AID-PROS5>3.0.CO;2-4","article-title":"Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro","volume":"38","author":"Goepel","year":"1999","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.lfs.2022.120931_bb0120","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0","article-title":"Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH","volume":"40","author":"Bayne","year":"1999","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0306-3623(95)00094-1","article-title":"Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle","volume":"27","author":"Gutierrez","year":"1996","journal-title":"Gen. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2022.120931_bb0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jep.2013.12.030","article-title":"Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility","volume":"152","author":"Chua","year":"2014","journal-title":"J. Ethnopharmacol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0135","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/1097-0045(20010215)46:3<226::AID-PROS1027>3.0.CO;2-R","article-title":"Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo?","volume":"46","author":"Goepel","year":"2001","journal-title":"Prostate"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2022.120931_bb0140","first-page":"S27","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2021\/22: G protein-coupled receptors","volume":"178","author":"Alexander","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2022.120931_bb0145","unstructured":"PubChem Compound Summary for CID 8058, Hexane. National Center for Biotechnology Information."},{"key":"10.1016\/j.lfs.2022.120931_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119771","article-title":"Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction","volume":"281","author":"Tamalunas","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2022.120931_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.884057","article-title":"Inhibition of human prostate and bladder smooth muscle contraction, vasoconstriction of porcine renal and coronary arteries, and growth-related functions of prostate stromal cells by presumed small molecule G\u03b1q\/11 inhibitor, YM-254890","volume":"13","author":"Tamalunas","year":"2022","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.119.118927","article-title":"New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology","volume":"97","author":"Michel","year":"2020","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.lfs.2022.120931_bb0165","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bph.14153","article-title":"Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers","volume":"175","author":"Curtis","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.lfs.2022.120931_bb0170","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/pros.23293","article-title":"Non-adrenergic, tamsulosin-insensitive smooth muscle contraction is sufficient to replace alpha1 -adrenergic tension in the human prostate","volume":"77","author":"Hennenberg","year":"2017","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.lfs.2022.120931_bb0175","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00210-020-02044-4","article-title":"Purinergic smooth muscle contractions in the human prostate: estimation of relevance and characterization of different agonists","volume":"394","author":"Spek","year":"2021","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0180","doi-asserted-by":"crossref","first-page":"F47","DOI":"10.1152\/ajprenal.00125.2017","article-title":"Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate","volume":"314","author":"Herlemann","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.lfs.2022.120931_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172985","article-title":"Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by alpha1-blockers","volume":"873","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2022.120931_bb0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-3-642-16499-6_16","article-title":"Muscarinic acetylcholine receptors in the urinary tract","volume":"202","author":"Andersson","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.lfs.2022.120931_bb0195","article-title":"Serenoa repens for benign prostatic hyperplasia","volume":"2","author":"Tacklind","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.lfs.2022.120931_bb0200","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the american urological association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J. Urol."},{"issue":"25","key":"10.1016\/j.lfs.2022.120931_bb0205","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G","article-title":"Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia","volume":"45","author":"Vacherot","year":"2000","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0220","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000019570","article-title":"Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies","volume":"33","author":"Paubert-Braquet","year":"1998","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.lfs.2022.120931_bb0225","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/ATVBAHA.115.305310","article-title":"Collectivization of vascular smooth muscle cells via TGF-beta-Cadherin-11-dependent adhesive switching","volume":"35","author":"Balint","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.lfs.2022.120931_bb0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2490-14-63","article-title":"Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms","volume":"14","author":"De Monte","year":"2014","journal-title":"BMC Urol."},{"issue":"9","key":"10.1016\/j.lfs.2022.120931_bb0235","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.3390\/nu5093617","article-title":"Fatty acid and phytosterol content of commercial saw palmetto supplements","volume":"5","author":"Penugonda","year":"2013","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00216-008-2297-0","article-title":"Development of saw palmetto (Serenoa repens) fruit and extract standard reference materials","volume":"392","author":"Schantz","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"issue":"2\u20133","key":"10.1016\/j.lfs.2022.120931_bb0245","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ejphar.2009.09.037","article-title":"Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats","volume":"626","author":"Veeresh Babu","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.lfs.2022.120931_bb0250","first-page":"684","article-title":"Effect of oleic, lauric and myristic acids on phenylephrine-induced contractions of isolated rat vas deferens","volume":"49","author":"Arruzazabala","year":"2011","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.lfs.2022.120931_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120046","article-title":"Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K\/Akt pathway","volume":"286","author":"Zhu","year":"2021","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.lfs.2022.120931_bb0260","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pros.20322","article-title":"Saw palmetto is an indirectly acting sympathomimetic in the rat-isolated prostate gland","volume":"66","author":"Cao","year":"2006","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0265","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pros.21223","article-title":"Ethanol extracts of saw palmetto contain the indirectly acting sympathomimetic: tyramine","volume":"71","author":"Chua","year":"2011","journal-title":"Prostate"},{"issue":"8964","key":"10.1016\/j.lfs.2022.120931_bb0270","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0140-6736(95)91085-9","article-title":"Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group","volume":"345","author":"Berges","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0275","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/01635589809514709","article-title":"Beta-sitosterol activates the sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells","volume":"32","author":"von Holtz","year":"1998","journal-title":"Nutr. Cancer"},{"issue":"6","key":"10.1016\/j.lfs.2022.120931_bb0280","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00008469-200112000-00005","article-title":"In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells","volume":"10","author":"Awad","year":"2001","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.lfs.2022.120931_bb0285","first-page":"153","article-title":"Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate","volume":"46","author":"Cabeza","year":"2003","journal-title":"Proc. West. Pharmacol. Soc."},{"issue":"3","key":"10.1016\/j.lfs.2022.120931_bb0290","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbrc.2008.11.114","article-title":"Characterizing components of the saw palmetto berry extract (SPBE) on prostate cancer cell growth and traction","volume":"379","author":"Scholtysek","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0295","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-8223(21)05668-6","article-title":"Sterol content of foods of plant origin","volume":"73","author":"Weihrauch","year":"1978","journal-title":"J. Am. Diet. Assoc."},{"key":"10.1016\/j.lfs.2022.120931_bb0300","series-title":"European Union Herbal Monograph on Serenoa repens (W. Bartram) Small, fructus","author":"Committee on Herbal Medicinal Products","year":"2015"},{"key":"10.1016\/j.lfs.2022.120931_bb0305","article-title":"Serenoa repens capsules: a bioequivalence study","volume":"15","author":"Bernardi","year":"1994","journal-title":"Acta Toxicol. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2022.120931_bb0310","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF03189787","article-title":"Distribution study of radioactivity in rats after oral administration of the lipido\/sterolic extract ofSerenoa repens (Permixon\u00ae) supplemented with [1-14C]-lauric acid,[1-14C]-oleic acid or [4-14C]-\u03b2-sitosterol","volume":"22","author":"Chevalier","year":"1997","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.lfs.2022.120931_bb0315","article-title":"Re-evaluation of fatty acids (E 570) as a food additive","volume":"15","author":"Additives","year":"2017","journal-title":"EFSA J."},{"issue":"4","key":"10.1016\/j.lfs.2022.120931_bb0320","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000161128","article-title":"Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells","volume":"82","author":"Scaglione","year":"2008","journal-title":"Pharmacology"},{"issue":"5","key":"10.1016\/j.lfs.2022.120931_bb0325","first-page":"569","article-title":"Comparison of the potency of 10 different brands of Serenoa repens extracts","volume":"16","author":"Scaglione","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522006312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522006312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:04:09Z","timestamp":1758402249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522006312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":65,"alternative-id":["S0024320522006312"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120931","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Permixon\u00ae, hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"120931"}}